메뉴 건너뛰기




Volumn 2015, Issue , 2015, Pages

Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ALENDRONIC ACID; ANDROGEN RECEPTOR ANTAGONIST; ANTIBODY; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 6 ANTIBODY; CABOZANTINIB; CALCIUM; CLODRONIC ACID; DENOSUMAB; DICKKOPF 1 PROTEIN ANTIBODY; DOCETAXEL; ENDOTHELIN RECEPTOR ANTAGONIST; ENZALUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; ORTERONEL; PAMIDRONIC ACID; PLACEBO; RADIOISOTOPE; RADIUM 223; SCLEROSTIN ANTIBODY; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

EID: 84937147529     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/838202     Document Type: Review
Times cited : (27)

References (68)
  • 1
    • 0242669907 scopus 로고    scopus 로고
    • Costs of prostate cancer, metastatic to the bone, in the Netherlands
    • M. T. Groot, C. G. G. B. Kruger, R. C. M. Pelger, and C. A. Uylde Groot, "Costs of prostate cancer, metastatic to the bone, in the Netherlands, " European Urology, vol. 43, no. 3, pp. 226-232, 2003.
    • (2003) European Urology , vol.43 , Issue.3 , pp. 226-232
    • Groot, M.T.1    Kruger, C.G.G.B.2    Pelger, R.C.M.3    Uylde Groot, C.A.4
  • 2
    • 84891809097 scopus 로고    scopus 로고
    • EAU guidelines on prostate cancer. Part II. Treatment of advanced, relapsing, and castration-resistant prostate cancer
    • A. Heidenreich, P. J. Bastian, J. Bellmunt et al., "EAU guidelines on prostate cancer. Part II. Treatment of advanced, relapsing, and castration-resistant prostate cancer, " European Urology, vol. 65, no. 2, pp. 467-479, 2014.
    • (2014) European Urology , vol.65 , Issue.2 , pp. 467-479
    • Heidenreich, A.1    Bastian, P.J.2    Bellmunt, J.3
  • 4
    • 84857957486 scopus 로고    scopus 로고
    • Bone health management in prostate cancer patients receiving androgen deprivation therapy
    • V. Dhanapal and D. J. Reeves, "Bone health management in prostate cancer patients receiving androgen deprivation therapy, " Journal of Oncology Pharmacy Practice, vol. 18, no. 1, pp. 84-90, 2012.
    • (2012) Journal of Oncology Pharmacy Practice , vol.18 , Issue.1 , pp. 84-90
    • Dhanapal, V.1    Reeves, D.J.2
  • 5
    • 33748280677 scopus 로고    scopus 로고
    • Changing patterns of pelvic lymphadenectomy for prostate cancer: Results from CaPSURE
    • J. Kawakami, M. V. Meng, N. Sadetsky, D. M. Latini, J. Duchane, and P. R. Carroll, "Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE, " Journal of Urology, vol. 176, no. 4, pp. 1382-1386, 2006.
    • (2006) Journal of Urology , vol.176 , Issue.4 , pp. 1382-1386
    • Kawakami, J.1    Meng, M.V.2    Sadetsky, N.3    Latini, D.M.4    Duchane, J.5    Carroll, P.R.6
  • 9
    • 84864283300 scopus 로고    scopus 로고
    • Muscles, exercise and obesity: Skeletal muscle as a secretory organ
    • B. K. Pedersen and M. A. Febbraio, "Muscles, exercise and obesity: skeletal muscle as a secretory organ, " Nature Reviews Endocrinology, vol. 8, no. 8, pp. 457-465, 2012.
    • (2012) Nature Reviews Endocrinology , vol.8 , Issue.8 , pp. 457-465
    • Pedersen, B.K.1    Febbraio, M.A.2
  • 10
    • 84907482751 scopus 로고    scopus 로고
    • Muscle and bone effects of androgen deprivation therapy: Current and emerging therapies
    • A. S. Cheung, J. D. Zajac, andM. Grossmann, "Muscle and bone effects of androgen deprivation therapy: current and emerging therapies, " Endocrine Related Cancer, vol. 21, no. 5, pp. R371-R394, 2014.
    • (2014) Endocrine Related Cancer , vol.21 , Issue.5 , pp. R371-R394
    • Cheung, A.S.1    Zajac, J.D.2    Grossmann, M.3
  • 11
    • 69049105440 scopus 로고    scopus 로고
    • Denosumab in men receiving androgen-deprivation therapy for prostate cancer
    • M. R. Smith, B. Egerdie, N. H. Toriz et al., "Denosumab in men receiving androgen-deprivation therapy for prostate cancer, " The New England Journal of Medicine, vol. 361, no. 8, pp. 745-755, 2009.
    • (2009) The New England Journal of Medicine , vol.361 , Issue.8 , pp. 745-755
    • Smith, M.R.1    Egerdie, B.2    Toriz, N.H.3
  • 12
    • 84857042883 scopus 로고    scopus 로고
    • Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: A systematic review and metaanalysis
    • A. Serpa Neto, M. Tobias-Machado, M. A. P. Esteves et al., "Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and metaanalysis, " Prostate Cancer and Prostatic Diseases, vol. 15, no. 1, pp. 36-44, 2012.
    • (2012) Prostate Cancer and Prostatic Diseases , vol.15 , Issue.1 , pp. 36-44
    • Serpa Neto, A.1    Tobias-Machado, M.2    Esteves, M.A.P.3
  • 13
    • 79953751008 scopus 로고    scopus 로고
    • Osteoporosis: Now and the future
    • T. D. Rachner, S. Khosla, and L. C. Hofbauer, "Osteoporosis: now and the future, " The Lancet, vol. 377, no. 9773, pp. 1276-1287, 2011.
    • (2011) The Lancet , vol.377 , Issue.9773 , pp. 1276-1287
    • Rachner, T.D.1    Khosla, S.2    Hofbauer, L.C.3
  • 14
    • 84896130208 scopus 로고    scopus 로고
    • Dickkopf-1 as a mediator and novel target in malignant bone disease
    • T. D. Rachner, A. Göbel, P. Benad-Mehner, L. C. Hofbauer, and M. Rauner, "Dickkopf-1 as a mediator and novel target in malignant bone disease, " Cancer Letters, vol. 346, no. 2, pp. 172-177, 2014.
    • (2014) Cancer Letters , vol.346 , Issue.2 , pp. 172-177
    • Rachner, T.D.1    Göbel, A.2    Benad-Mehner, P.3    Hofbauer, L.C.4    Rauner, M.5
  • 15
    • 84893044528 scopus 로고    scopus 로고
    • Romosozumab in postmenopausal women with low bone mineral density
    • M. R. McClung, A. Grauer, S. Boonen et al., "Romosozumab in postmenopausal women with low bone mineral density, " The New England Journal of Medicine, vol. 370, no. 5, pp. 412-420, 2014.
    • (2014) The New England Journal of Medicine , vol.370 , Issue.5 , pp. 412-420
    • McClung, M.R.1    Grauer, A.2    Boonen, S.3
  • 16
    • 84899099995 scopus 로고    scopus 로고
    • Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids
    • B. Garcá-Fontana, S. Morales-Santana, M. Varsavsky et al., "Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids, " Osteoporosis International, vol. 25, no. 2, pp. 645-651, 2014.
    • (2014) Osteoporosis International , vol.25 , Issue.2 , pp. 645-651
    • Garcá-Fontana, B.1    Morales-Santana, S.2    Varsavsky, M.3
  • 17
    • 71849104052 scopus 로고    scopus 로고
    • Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation
    • R. R. Gomes Jr., P. Buttke, E. M. Paul, and R. A. Sikes, "Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation, " Clinical and Experimental Metastasis, vol. 26, no. 7, pp. 641-651, 2009.
    • (2009) Clinical and Experimental Metastasis , vol.26 , Issue.7 , pp. 641-651
    • Gomes, R.R.1    Buttke, P.2    Paul, E.M.3    Sikes, R.A.4
  • 18
    • 84930898587 scopus 로고    scopus 로고
    • Bone-related parameters are the main prognostic factors for overall survival in men with bonemetastases fromcastration-resistant prostate cancer
    • K. Fizazi, C. Massard, M. Smith et al., "Bone-related parameters are the main prognostic factors for overall survival in men with bonemetastases fromcastration-resistant prostate cancer, " European Urology, 2014.
    • (2014) European Urology
    • Fizazi, K.1    Massard, C.2    Smith, M.3
  • 19
    • 84892442211 scopus 로고    scopus 로고
    • Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event
    • N. M. Hahn, C. T. Yiannoutsos, K. Kirkpatrick, J. Sharma, and C. J. Sweeney, "Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event, " Clinical Genitourinary Cancer, vol. 12, no. 1, pp. 33. e4-40. e4, 2014.
    • (2014) Clinical Genitourinary Cancer , vol.12 , Issue.1 , pp. 33e4-40e4
    • Hahn, N.M.1    Yiannoutsos, C.T.2    Kirkpatrick, K.3    Sharma, J.4    Sweeney, C.J.5
  • 20
    • 0034659963 scopus 로고    scopus 로고
    • Biochemical markers and skeletal metastases
    • L. M. Demers, L. Costa, and A. Lipton, "Biochemical markers and skeletal metastases, " Cancer, vol. 88, no. 12, pp. 2919-2926, 2000.
    • (2000) Cancer , vol.88 , Issue.12 , pp. 2919-2926
    • Demers, L.M.1    Costa, L.2    Lipton, A.3
  • 21
    • 79953329365 scopus 로고    scopus 로고
    • Niche competition and cancer metastasis to bone
    • L. G. Schuettpelz andD. C. Link, "Niche competition and cancer metastasis to bone, "The Journal of Clinical Investigation, vol. 121, no. 4, pp. 1253-1255, 2011.
    • (2011) The Journal of Clinical Investigation , vol.121 , Issue.4 , pp. 1253-1255
    • Schuettpelz, L.G.1    Link, C.D.2
  • 22
    • 0029085123 scopus 로고
    • Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate
    • J. B. Nelson, S. P. Hedican, D. J. George et al., "Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate, " Nature Medicine, vol. 1, no. 9, pp. 944-949, 1995.
    • (1995) Nature Medicine , vol.1 , Issue.9 , pp. 944-949
    • Nelson, J.B.1    Hedican, S.P.2    George, D.J.3
  • 23
    • 33846624243 scopus 로고    scopus 로고
    • Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation
    • G. A. Clines, K. S. Mohammad, Y. Bao et al., "Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation, " Molecular Endocrinology, vol. 21, no. 2, pp. 486-498, 2007.
    • (2007) Molecular Endocrinology , vol.21 , Issue.2 , pp. 486-498
    • Clines, G.A.1    Mohammad, K.S.2    Bao, Y.3
  • 25
    • 84868200731 scopus 로고    scopus 로고
    • Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone
    • J. B. Nelson, K. Fizazi, K. Miller et al., "Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone, " Cancer, vol. 118, no. 22, pp. 5709-5718, 2012.
    • (2012) Cancer , vol.118 , Issue.22 , pp. 5709-5718
    • Nelson, J.B.1    Fizazi, K.2    Miller, K.3
  • 26
    • 84879466638 scopus 로고    scopus 로고
    • Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer
    • K. S. Fizazi, C. S. Higano, J. B. Nelson et al., "Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer, " Journal of Clinical Oncology, vol. 31, no. 14, pp. 1740-1747, 2013.
    • (2013) Journal of Clinical Oncology , vol.31 , Issue.14 , pp. 1740-1747
    • Fizazi, K.S.1    Higano, C.S.2    Nelson, J.B.3
  • 27
    • 12344291865 scopus 로고    scopus 로고
    • Bone morphogenetic proteins
    • D. Chen, M. Zhao, and G. R. Mundy, "Bone morphogenetic proteins, " Growth Factors, vol. 22, no. 4, pp. 233-241, 2004.
    • (2004) Growth Factors , vol.22 , Issue.4 , pp. 233-241
    • Chen, D.1    Zhao, M.2    Mundy, G.R.3
  • 28
    • 24944480253 scopus 로고    scopus 로고
    • Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism
    • J. Dai, J. Keller, J. Zhang, Y. Lu, Z. Yao, and E. T. Keller, "Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism, " Cancer Research, vol. 65, no. 18, pp. 8274-8285, 2005.
    • (2005) Cancer Research , vol.65 , Issue.18 , pp. 8274-8285
    • Dai, J.1    Keller, J.2    Zhang, J.3    Lu, Y.4    Yao, Z.5    Keller, E.T.6
  • 29
    • 33847025382 scopus 로고    scopus 로고
    • Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases
    • R. Schweninger, C. A. Rentsch, A. Wetterwald et al., "Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases, " American Journal of Pathology, vol. 170, no. 1, pp. 160-175, 2007.
    • (2007) American Journal of Pathology , vol.170 , Issue.1 , pp. 160-175
    • Schweninger, R.1    Rentsch, C.A.2    Wetterwald, A.3
  • 30
    • 0033199111 scopus 로고    scopus 로고
    • Osteonectin promotes prostate cancer cell migration and invasion: A possible mechanism for metastasis to bone
    • K. Jacob, M. Webber, D. Benayahu, and H. K. Kleinman, "Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone, " Cancer Research, vol. 59, no. 17, pp. 4453-4457, 1999.
    • (1999) Cancer Research , vol.59 , Issue.17 , pp. 4453-4457
    • Jacob, K.1    Webber, M.2    Benayahu, D.3    Kleinman, H.K.4
  • 31
    • 0346725927 scopus 로고    scopus 로고
    • Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis
    • J. Rubin, L. W. K. Chung, X. Fan et al., "Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis, " Prostate, vol. 58, no. 1, pp. 41-49, 2004.
    • (2004) Prostate , vol.58 , Issue.1 , pp. 41-49
    • Rubin, J.1    Chung, L.W.K.2    Fan, X.3
  • 32
    • 84889086250 scopus 로고    scopus 로고
    • Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: A 15-year study in two large US health systems
    • G. Oster, L. Lamerato, A. G. Glass et al., "Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems, " Supportive Care in Cancer, vol. 21, no. 12, pp. 3279-3286, 2013.
    • (2013) Supportive Care in Cancer , vol.21 , Issue.12 , pp. 3279-3286
    • Oster, G.1    Lamerato, L.2    Glass, A.G.3
  • 33
    • 2942518111 scopus 로고    scopus 로고
    • Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
    • F. Saad, D. M. Gleason, R. Murray et al., "Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, " Journal of the National Cancer Institute, vol. 96, no. 11, pp. 879-882, 2004.
    • (2004) Journal of the National Cancer Institute , vol.96 , Issue.11 , pp. 879-882
    • Saad, F.1    Gleason, D.M.2    Murray, R.3
  • 34
    • 0642337996 scopus 로고    scopus 로고
    • Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer
    • E. J. Small, M. R. Smith, J. J. Seaman, S. Petrone, and M. O. Kowalski, "Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer, " Journal of ClinicalOncology, vol. 21, no. 23, pp. 4277-4284, 2003.
    • (2003) Journal of ClinicalOncology , vol.21 , Issue.23 , pp. 4277-4284
    • Small, E.J.1    Smith, M.R.2    Seaman, J.J.3    Petrone, S.4    Kowalski, M.O.5
  • 35
    • 0141688330 scopus 로고    scopus 로고
    • Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain
    • D. S. Ernst, I. F. Tannock, E. W. Winquist et al., "Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain, " Journal of Clinical Oncology, vol. 21, no. 17, pp. 3335-3342, 2003.
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.17 , pp. 3335-3342
    • Ernst, D.S.1    Tannock, I.F.2    Winquist, E.W.3
  • 36
    • 69149084971 scopus 로고    scopus 로고
    • Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: Longterm overall survival results from the MRC PR04 and PR05 randomised controlled trials
    • D. P. Dearnaley, M. D. Mason, M. K. Parmar, K. Sanders, and M. R. Sydes, "Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: longterm overall survival results from the MRC PR04 and PR05 randomised controlled trials, " The Lancet Oncology, vol. 10, no. 9, pp. 872-876, 2009.
    • (2009) The Lancet Oncology , vol.10 , Issue.9 , pp. 872-876
    • Dearnaley, D.P.1    Mason, M.D.2    Parmar, M.K.3    Sanders, K.4    Sydes, M.R.5
  • 37
    • 84873268474 scopus 로고    scopus 로고
    • Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A
    • Y. Cirak, U. Varol, H. Atmaca et al., "Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A, " BJU International, vol. 110, no. 11, pp. E1147-E1154, 2012.
    • (2012) BJU International , vol.110 , Issue.11 , pp. E1147-E1154
    • Cirak, Y.1    Varol, U.2    Atmaca, H.3
  • 38
    • 84876423480 scopus 로고    scopus 로고
    • Altered expression of farnesyl pyrophosphate synthase in prostate cancer: Evidence for a role of the mevalonate pathway in disease progression?
    • T. Todenhöfer, J. Hennenlotter, U. Kühs et al., "Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?" World Journal of Urology, vol. 31, no. 2, pp. 345-350, 2013.
    • (2013) World Journal of Urology , vol.31 , Issue.2 , pp. 345-350
    • Todenhöfer, T.1    Hennenlotter, J.2    Kühs, U.3
  • 39
    • 14544291047 scopus 로고    scopus 로고
    • Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures
    • H. X. Jiang, S. R. Majumdar, D. A. Dick et al., "Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures, " Journal of Bone and Mineral Research, vol. 20, no. 3, pp. 494-500, 2005.
    • (2005) Journal of Bone and Mineral Research , vol.20 , Issue.3 , pp. 494-500
    • Jiang, H.X.1    Majumdar, S.R.2    Dick, D.A.3
  • 40
    • 79952360832 scopus 로고    scopus 로고
    • Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, doubleblind study
    • K. Fizazi, M. Carducci, M. Smith et al., "Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, doubleblind study, " The Lancet, vol. 377, no. 9768, pp. 813-822, 2011.
    • (2011) The Lancet , vol.377 , Issue.9768 , pp. 813-822
    • Fizazi, K.1    Carducci, M.2    Smith, M.3
  • 41
    • 84889093279 scopus 로고    scopus 로고
    • Pain and healthrelated quality of life in patients with advanced solid tumours and bonemetastases: Integrated results fromthree randomized, double-blind studies of denosumab and zoledronic acid
    • R. von Moos, J.-J. Body, B. Egerdie et al., "Pain and healthrelated quality of life in patients with advanced solid tumours and bonemetastases: integrated results fromthree randomized, double-blind studies of denosumab and zoledronic acid, " Supportive Care in Cancer, vol. 21, no. 12, pp. 3497-3507, 2013.
    • (2013) Supportive Care in Cancer , vol.21 , Issue.12 , pp. 3497-3507
    • Von Moos, R.1    Body, J.-J.2    Egerdie, B.3
  • 42
    • 84880428467 scopus 로고    scopus 로고
    • Alpha emitter radium-223 and survival in metastatic prostate cancer
    • C. Parker, S. Nilsson DHeinrich, S. I. Helle et al., "Alpha emitter radium-223 and survival in metastatic prostate cancer, "TheNew England Journal of Medicine, vol. 369, no. 3, pp. 213-223, 2013.
    • (2013) TheNew England Journal of Medicine , vol.369 , Issue.3 , pp. 213-223
    • Parker, C.1    Nilsson Dheinrich, S.2    Helle, S.I.3
  • 43
    • 84937136684 scopus 로고    scopus 로고
    • Assessing the benefit of bone-targeted therapies in prostate cancer, is the devil in the endpoint's definition?
    • B. Tombal, "Assessing the benefit of bone-targeted therapies in prostate cancer, is the devil in the endpoint's definition?" Annals of Oncology, 2014.
    • (2014) Annals of Oncology
    • Tombal, B.1
  • 44
    • 84937133846 scopus 로고    scopus 로고
    • Denosumab for the prevention of skeletal complications in metastatic castrationresistant prostate cancer: Comparison of skeletal-related events and symptomatic skeletal events
    • M. R. Smith, R. E. Coleman, L. Klotz et al., "Denosumab for the prevention of skeletal complications in metastatic castrationresistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events, " Annals of Oncology, 2014.
    • (2014) Annals of Oncology
    • Smith, M.R.1    Coleman, R.E.2    Klotz, L.3
  • 45
    • 18644373689 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
    • T. Chen, J. Berenson, R. Vescio et al., "Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases, " Journal of Clinical Pharmacology, vol. 42, no. 11, pp. 1228-1236, 2002.
    • (2002) Journal of Clinical Pharmacology , vol.42 , Issue.11 , pp. 1228-1236
    • Chen, T.1    Berenson, J.2    Vescio, R.3
  • 46
    • 84870862207 scopus 로고    scopus 로고
    • Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: Results of a randomized phase II trial
    • K. Fizazi, L. Bosserman, G. Gao, T. Skacel, and R. Markus, "Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial, " Journal of Urology, vol. 189, no. 1, pp. S51-S58, 2013.
    • (2013) Journal of Urology , vol.189 , Issue.1 , pp. S51-S58
    • Fizazi, K.1    Bosserman, L.2    Gao, G.3    Skacel, T.4    Markus, R.5
  • 47
    • 0042331464 scopus 로고    scopus 로고
    • A doubleblind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)
    • D. P. Dearnaley, M. R. Sydes, M. D. Mason et al., "A doubleblind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial), " Journal of the National Cancer Institute, vol. 95, no. 17, pp. 1300-1311, 2003.
    • (2003) Journal of the National Cancer Institute , vol.95 , Issue.17 , pp. 1300-1311
    • Dearnaley, D.P.1    Sydes, M.R.2    Mason, M.D.3
  • 48
    • 84901944163 scopus 로고    scopus 로고
    • Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (alliance)
    • M. R. Smith, S. Halabi, C. J. Ryan et al., "Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance), " Journal of Clinical Oncology, vol. 32, no. 11, pp. 1143-1150, 2014.
    • (2014) Journal of Clinical Oncology , vol.32 , Issue.11 , pp. 1143-1150
    • Smith, M.R.1    Halabi, S.2    Ryan, C.J.3
  • 49
    • 79952403539 scopus 로고    scopus 로고
    • Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases
    • N. K. Thudi, C. K. Martin, S. Murahari et al., "Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases, " Prostate, vol. 71, no. 6, pp. 615-625, 2011.
    • (2011) Prostate , vol.71 , Issue.6 , pp. 615-625
    • Thudi, N.K.1    Martin, C.K.2    Murahari, S.3
  • 50
    • 15444365985 scopus 로고    scopus 로고
    • Bone turnover mediates preferential localization of prostate cancer in the skeleton
    • A. Schneider, L. M. Kalikin, A. C. Mattos et al., "Bone turnover mediates preferential localization of prostate cancer in the skeleton, " Endocrinology, vol. 146, no. 4, pp. 1727-1736, 2005.
    • (2005) Endocrinology , vol.146 , Issue.4 , pp. 1727-1736
    • Schneider, A.1    Kalikin, L.M.2    Mattos, A.C.3
  • 51
    • 0344844468 scopus 로고    scopus 로고
    • Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone
    • J. Zhang, J. Dai, Z. Yao, Y. Lu, W. Dougall, and E. T. Keller, "Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone, " Cancer Research, vol. 63, no. 22, pp. 7883-7890, 2003.
    • (2003) Cancer Research , vol.63 , Issue.22 , pp. 7883-7890
    • Zhang, J.1    Dai, J.2    Yao, Z.3    Lu, Y.4    Dougall, W.5    Keller, E.T.6
  • 52
    • 34447273333 scopus 로고    scopus 로고
    • Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: Medical research council PR04 (ISRCTN61384873)
    • M. D. Mason, M. R. Sydes, J. Glaholm et al., "Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: medical research council PR04 (ISRCTN61384873), " Journal of the National Cancer Institute, vol. 99, pp. 765-776, 2007.
    • (2007) Journal of the National Cancer Institute , vol.99 , pp. 765-776
    • Mason, M.D.1    Sydes, M.R.2    Glaholm, J.3
  • 53
    • 21144438189 scopus 로고    scopus 로고
    • Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
    • M. R. Smith, F. Kabbinavar, F. Saad et al., "Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer, " Journal of ClinicalOncology, vol. 23, no. 13, pp. 2918-2925, 2005.
    • (2005) Journal of ClinicalOncology , vol.23 , Issue.13 , pp. 2918-2925
    • Smith, M.R.1    Kabbinavar, F.2    Saad, F.3
  • 54
    • 84922256444 scopus 로고    scopus 로고
    • Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: Efficacy and safety results of the Zometa European Study (ZEUS)
    • M. Wirth, T. Tammela, V. Cicalese et al., "Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS), " European Urology, 2014.
    • (2014) European Urology
    • Wirth, M.1    Tammela, T.2    Cicalese, V.3
  • 55
    • 84937129011 scopus 로고    scopus 로고
    • Zometa European Study (ZEUS): Another failed crusade for the holy grail of prostate cancer bone metastases prevention?
    • B. Tombal, "Zometa European Study (ZEUS): another failed crusade for the holy grail of prostate cancer bone metastases prevention?" European Urology, 2014.
    • (2014) European Urology
    • Tombal, B.1
  • 56
    • 84922255874 scopus 로고    scopus 로고
    • Reply from authors re: Bertrand tombal. Zometa european study (zeus): Another failed crusade for the holy grail of prostate cancer bone metastases prevention? Eur urol
    • zeus: the quest for the holy grail of prostate cancer bone metastases prevention continues
    • W. P. J. Witjes, A. Patel, and M. Wirth, "Reply from Authors re: Bertrand Tombal. Zometa European Study (ZEUS): another Failed Crusade for the Holy Grail of Prostate Cancer Bone Metastases Prevention? Eur Urol. In press. http://dx. doi. org/ 10. 1016/j. eururo. 2014. 03. 009. ZEUS: The Quest for the Holy Grail of Prostate Cancer Bone Metastases Prevention Continues, " European Urology, 2014.
    • (2014) European Urology
    • Witjes, W.P.J.1    Patel, A.2    Wirth, M.3
  • 57
    • 84906940239 scopus 로고    scopus 로고
    • Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03. 04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer
    • J. W. Denham, M. Nowitz, D. Joseph et al., "Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03. 04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer, " BJU International, vol. 114, no. 3, pp. 344-353, 2014.
    • (2014) BJU International , vol.114 , Issue.3 , pp. 344-353
    • Denham, J.W.1    Nowitz, M.2    Joseph, D.3
  • 58
    • 84855516339 scopus 로고    scopus 로고
    • Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebocontrolled trial
    • M. R. Smith, F. Saad, R. Coleman et al., "Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebocontrolled trial, " The Lancet, vol. 379, no. 9810, pp. 39-46, 2012.
    • (2012) The Lancet , vol.379 , Issue.9810 , pp. 39-46
    • Smith, M.R.1    Saad, F.2    Coleman, R.3
  • 59
    • 84891687896 scopus 로고    scopus 로고
    • Denosumab and bone metastasis-free survival in men with nonmetastatic castrationresistant prostate cancer: Exploratory analyses by baseline prostate-specific antigen doubling time
    • M. R. Smith, F. Saad, S. Oudard et al., "Denosumab and bone metastasis-free survival in men with nonmetastatic castrationresistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time, " Journal of Clinical Oncology, vol. 31, no. 30, pp. 3800-3806, 2013.
    • (2013) Journal of Clinical Oncology , vol.31 , Issue.30 , pp. 3800-3806
    • Smith, M.R.1    Saad, F.2    Oudard, S.3
  • 60
    • 84907479141 scopus 로고    scopus 로고
    • Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone
    • P. D. Ottewell, N. Wang, J. Meek et al., "Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone, " Endocrine Related Cancer, vol. 21, no. 5, pp. 769-781, 2014.
    • (2014) Endocrine Related Cancer , vol.21 , Issue.5 , pp. 769-781
    • Ottewell, P.D.1    Wang, N.2    Meek, J.3
  • 61
    • 84908575897 scopus 로고    scopus 로고
    • Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 AFFIRM trial
    • K. Fizazi, H. I. Scher, K. Miller et al., "Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial, " The Lancet Oncology, vol. 15, no. 10, pp. 1147-1156, 2014.
    • (2014) The Lancet Oncology , vol.15 , Issue.10 , pp. 1147-1156
    • Fizazi, K.1    Scher, H.I.2    Miller, K.3
  • 62
    • 84870243969 scopus 로고    scopus 로고
    • Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients withmetastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomised trial
    • C. J. Logothetis, E. Basch, A. Molina et al., "Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients withmetastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial, " The Lancet Oncology, vol. 13, no. 12, pp. 1210-1217, 2012.
    • (2012) The Lancet Oncology , vol.13 , Issue.12 , pp. 1210-1217
    • Logothetis, C.J.1    Basch, E.2    Molina, A.3
  • 63
    • 84901638475 scopus 로고    scopus 로고
    • Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial
    • O. Sartor, R. Coleman, S. Nilsson et al., "Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial, " The Lancet Oncology, vol. 15, no. 7, pp. 738-746, 2014.
    • (2014) The Lancet Oncology , vol.15 , Issue.7 , pp. 738-746
    • Sartor, O.1    Coleman, R.2    Nilsson, S.3
  • 64
    • 84937141223 scopus 로고    scopus 로고
    • Time to first skeletalrelated event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial stratification factors analysis
    • R. Coleman, S. Fossa, A. Chodacki et al., "Time to first skeletalrelated event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial stratification factors analysis, " European Journal of Cancer, vol. 49, pp. S688-S688, 2013.
    • (2013) European Journal of Cancer , vol.49 , pp. S688-S688
    • Coleman, R.1    Fossa, S.2    Chodacki, A.3
  • 65
    • 84905170852 scopus 로고    scopus 로고
    • Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: Results of a phase II nonrandomized expansion study
    • M. R. Smith, C. J. Sweeney, P. G. Corn et al., "Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study, " Journal of Clinical Oncology, vol. 32, pp. 3391-3399, 2014.
    • (2014) Journal of Clinical Oncology , vol.32 , pp. 3391-3399
    • Smith, M.R.1    Sweeney, C.J.2    Corn, P.G.3
  • 67
    • 84898893682 scopus 로고    scopus 로고
    • Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial)
    • abstract 7
    • R. Dreicer, R. Jones, S. Oudard et al., "Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial), " Journal of Clinical Oncology, vol. 32, supplement 4, abstract 7, 2014.
    • (2014) Journal of Clinical Oncology , vol.32
    • Dreicer, R.1    Jones, R.2    Oudard, S.3
  • 68
    • 84937136206 scopus 로고    scopus 로고
    • Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC4 trial)
    • R. De Wit, K. Fizazi, V. Jinga et al., "Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC4 trial), " in Proceedings of the American Society of Clinical Oncology Meeting (ASCO '14), 2014.
    • (2014) Proceedings of the American Society of Clinical Oncology Meeting (ASCO '14)
    • De Wit, R.1    Fizazi, K.2    Jinga, V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.